Antibody drugs have reshaped how we treat diseases. By harnessing the immune system to destroy tumours or temper excessive inflammation in autoimmune disorders, these therapeutics have become ...
Pursuant to the transaction with Telix, ImaginAb has retained its lead imaging candidate, CD8 ImmunoPET, which is currently in Phase 2 clinical trials and has been licensed by numerous pharmaceutical ...
Chugai Pharm signs collaboration agreement with GSK's Global Health Unit for development of anti-dengue virus antibody: Tokyo Friday, January 31, 2025, 09:00 Hrs [IST] Chugai Phar ...
Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...
A new study shows how an anticancer drug triggers an "outside in" signal that gets it sucked into a cancer cell. The work, ...
A review of recent trends and remaining challenges in bispecific antibody (bsAb) production has been published.
A new study shows how an anticancer drug triggers an “outside in” signal that gets it sucked into a cancer cell.
Monoclonal antibodies, or mAbs, are important tools in medicine. These laboratory-made proteins are widely used in treatments ...
Apogee Therapeutics, Inc. (NASDAQ: APGE) has announced the dosing of the first patient in the part B portion of the phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback